Cannabis Research
CBD and Brain Cancer: Why Biomarker Changes Aren’t Enough

Key PointsCBD lowered corticosterone yet failed to improve forced-swim behavior in tumor-bearing…
View more
- CBD lowered corticosterone yet failed to improve forced-swim behavior in tumor-bearing rats.
- Opposite immune effects from CBD and temozolomide do not prove CBD reverses chemotherapy suppression.
- The study's five-day window and male-only rats limit conclusions about longer or female responses.
Can cannabidiol help relieve depression associated with glioblastoma while patients receive chemotherapy? Answering that question requires more than showing that CBD changes a stress hormone or influences brain cells. Researchers must establish whether those changes accompany meaningful improvements, and whether the benefits hold up in the presence of cancer.
A new study accepted by Neuroscience tested part of that question in male rats with experimentally induced glioblastoma.1 CBD produced measurable biological effects, but neither CBD alone nor its combination with temozolomide chemotherapy improved the behavioral measure used to assess antidepressant-like responses.
That result narrows a research hypothesis rather than closing the subject. Its value lies in showing where a promising biological signal stops short of demonstrating benefit, and how future experiments might bridge that gap.
Why Study CBD During Glioblastoma Treatment?
Glioblastoma is an aggressive brain cancer. Its psychological burden can involve the diagnosis itself, neurological changes, treatment effects, and the wider disruption of daily life. These overlapping influences make depression associated with brain cancer a particularly difficult problem to reproduce in a laboratory.
Temozolomide, often shortened to TMZ, is a chemotherapy drug used in glioblastoma treatment. The researchers wanted to investigate whether adding a potential antidepressant treatment could improve behavioral outcomes within a tumor-bearing animal model.
They examined CBD alongside fluoxetine, an established antidepressant, and metformin, a diabetes medication investigated here for potential antidepressant-like effects. Including these different drugs helped place CBD within a broader experimental question: how does the presence of a brain tumor affect responses to treatments that have shown promise elsewhere?
The rationale extends beyond any single experiment. A 2026 meta-analysis of 123 animal studies reported reductions in anxiety-like and depressive-like behaviors with CBD across several testing approaches. However, results depended partly on the behavioral test and underlying pathology. An encouraging average across animal studies cannot establish efficacy for a specific cancer-related condition.
How the CBD and Chemotherapy Experiment Worked
The researchers used 69 adult male Fischer 344 rats. They implanted RG2 glioblastoma cells into the right striatum, a brain region, and allowed the cells to proliferate for one week before beginning treatment.
The tumor cells were compatible with the rat strain. This approach, called a syngeneic model, allowed researchers to study treatment responses in a tumor environment without relying on implanted human cancer cells. It nevertheless remained an experimentally induced disease in rodents.
For five days, animals received TMZ at 25 milligrams per kilogram of body weight or a control preparation. Three hours later, they received CBD at 30 milligrams per kilogram, fluoxetine at 10 milligrams per kilogram, metformin at 100 milligrams per kilogram, or another control preparation. Drugs were administered by injection into the abdominal cavity.
These are experimental animal doses and delivery methods, not instructions for using retail CBD. The eight groups contained eight or nine rats each.
Behavior was assessed using the forced-swim test, which measures activity and immobility during a controlled swimming task. Researchers use it to investigate antidepressant-like drug responses. It does not measure a person’s experience of depression, and one test cannot capture the full condition.
CBD Changed Biological Measures Without Behavioral Improvement
The central finding was that CBD did not improve forced-swim performance. Combining it with TMZ did not produce the hoped-for antidepressant-like benefit. The other combinations also failed to demonstrate that benefit under the study conditions.
However, the drugs were biologically active. CBD and fluoxetine lowered corticosterone, a stress-related hormone. CBD increased measured lymphocyte and white blood cell counts, while TMZ reduced those counts. CBD also reduced NeuroD-positive cells, a marker associated with early stages of new neuron development, in the examined hippocampus.
Those findings resist a simple positive or negative label. A lower stress-related hormone did not establish improved behavior. Higher blood cell counts did not establish stronger protection against infection or cancer. A change in a developing-neuron marker did not establish a corresponding change in memory.
| Measure | Study Finding | Experimental Scope |
|---|---|---|
| Forced-swim behavior | No antidepressant-like benefit from CBD alone or with TMZ | One behavioral test after five treatment days |
| Corticosterone | Reduced by CBD and fluoxetine | Measured in plasma |
| NeuroD-positive cells | Reduced by TMZ and, overall, by CBD | Hippocampus in the hemisphere without tumor infiltration |
| Lymphocytes and white blood cells | Reduced by TMZ; increased with CBD treatment | No significant TMZ-by-CBD interaction detected |
Why Biomarkers Cannot Substitute for Symptom Relief
A biomarker is a measurable feature of a biological process. Think of it as a reading on a dashboard: it can show that a system has changed without establishing that the entire vehicle performs better.
Here, corticosterone provided evidence of a hormonal response. The behavioral test addressed a different question. Treating these measurements as interchangeable would erase the study’s most useful lesson.
There is another important distinction in the immune findings. Opposite effects from two drugs do not automatically demonstrate that one protects against the other. The researchers did not detect a significant interaction between TMZ and CBD on these measures. Describing CBD as reversing chemotherapy-related immune suppression would therefore go beyond the evidence.
This suggests a useful standard for evaluating cannabinoid research: specify the benefit before interpreting the measurements. Mood, cognition, immune function, and tumor control are separate outcomes. Progress in one cannot simply be carried across to the others.
Why Different CBD Studies Can Produce Different Results
CBD research varies in disease model, treatment duration, delivery route, and outcome. MyCannabis’s coverage of CBD and stress-linked memory deficits illustrates a different question involving developmental stress and later recognition memory. Those findings cannot predict antidepressant-like effects during glioblastoma treatment.
Similarly, research involving an experimental CBD implant for brain injury examines local delivery after a specific injury. It helps explain why “CBD affects the brain” is too broad a statement to guide therapeutic conclusions.
The glioblastoma experiment also had a narrow treatment window. The authors note that this tumor model has an average survival time of approximately 18 days after implantation, limiting opportunities for longer treatment and additional behavioral testing.
Five days may not capture effects requiring longer exposure. But that possibility is a hypothesis, not evidence that extending treatment would work. Likewise, testing only males leaves uncertainty about responses in females, while using one dose per drug prevents conclusions about other dosing schedules.
What Better Evidence Would Look Like
A stronger follow-up would connect biological activity with several independent measures of behavior and tolerability. Useful priorities include:
- Testing both sexes and comparing carefully justified treatment schedules.
- Adding behavioral measures beyond the forced-swim test.
- Measuring symptom-related outcomes alongside adverse effects and disease progression.
Human research also needs its own evidence pathway. A recent placebo-controlled CBD trial in people with primary brain tumors, reported after early termination, illustrates that investigators are already examining anxiety and depressive symptoms directly in patients. Its population and design differ from this rat experiment, so the two should not be treated as equivalent tests.
For readers, the practical distinction is between a research opportunity and an established treatment. This paper does not support using CBD to treat depression during glioblastoma care, nor does it test whether consumer products improve cancer survival. A purchasing guide cannot resolve those clinical questions.
The constructive next step is more precise research. CBD clearly changed several measurements in this experiment. Scientists can now ask which changes matter, whether they accompany benefits under other conditions, and what risks travel alongside them. That is a stronger foundation for progress than treating every biological change as proof of therapeutic success.
References:
1 Gálvez-Melero, L., Bihorac, J., Hadamitzky, M., & García-Fuster, M. J. (2026). Studying the pharmacological interaction of temozolomide chemotherapy with different antidepressant treatments in a rat glioblastoma model. Neuroscience. Advance online publication. https://doi.org/10.1016/j.neuroscience.2026.11.010












